Relmada Therapeutics Inc (OQ:RLMD)

Jan 04, 2024 06:30 am ET
Relmada Therapeutics Provides Corporate Update
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated
Nov 08, 2023 03:01 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
CORAL GABLES, Fla., Nov. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023. The Company will host a conference call today, Wednesday, November 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Nov 03, 2023 07:30 am ET
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
CORAL GABLES, Fla., Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, November 8, 2023.
Oct 11, 2023 08:30 am ET
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD) without detrimental CNS effectsMechanism of action of psilocybin distinct from that of GLP-1 drugs and could be complementaryCompany intends to initiate the single-ascending dose Phase 1 trial in patients in early 2024CORAL GABLES, Fla., Oct. 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnolog
Oct 09, 2023 07:30 am ET
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
CORAL GABLES, Fla., Oct. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in one-on-one investor meetings and a fireside chat on Thursday, October 12, 2023, at 2:30pm ET in New York, NY. Please find additional details about the event below.
Oct 06, 2023 07:30 am ET
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
Oct 02, 2023 12:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Sep 27, 2023 12:40 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Sep 21, 2023 09:31 am ET
Thinking about buying stock in TradeUP Acquisition Corp, Inventiva ADR, Relmada Therapeutics, P3 Health Partners, or Nikola Corp?
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UPTD, IVA, RLMD, PIII, and NKLA.
Sep 20, 2023 08:30 am ET
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detectedCORAL GABLES, Fla., Sept. 20, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced efficacy results for the de novo (or new to t
Aug 25, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Aug 11, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Relmada Therapeutics, Inc. (NYSE: RLMD), and DoubleVerify...
Aug 08, 2023 11:45 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Aug 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Relmada Therapeutics, Inc. (NYSE: RLMD), and DoubleVerify...
Aug 04, 2023 05:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Aug 01, 2023 07:30 am ET
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 8, 2023.
Jul 26, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), Arrival SA (NASDAQ: ARVL), FMC Corporation (NYSE: FMC), and Viasat, Inc. (NASDAQ:...
Jul 25, 2023 06:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jul 21, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), Relmada Therapeutics, Inc. (NASDAQ: RLMD), DoubleVerify Holdings, Inc. (NYSE: DV), and Castle...
Jul 17, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jul 16, 2023 08:40 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Relmada Therapeutics, Inc. (NYSE: RLMD), and DoubleVerify...
Jul 12, 2023 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jul 10, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Chegg, Inc. (NYSE: CHGG), and Relmada Therapeutics, Inc....
Jul 06, 2023 06:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jul 05, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Chegg, Inc. (NYSE: CHGG), and Relmada Therapeutics, Inc....
Jul 03, 2023 02:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jul 01, 2023 02:43 am ET
Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Seagate Technology Holdings Plc (NASDAQ: STX), Chegg, Inc. (NYSE: CHGG), Relmada Therapeutics, Inc. (NASDAQ: RLMD), and...
Jun 30, 2023 01:15 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jun 25, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), DoubleVerify Holdings, Inc. (NYSE: DV), Sanmina Corporation (NASDAQ: SANM), and...
Jun 20, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jun 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), Seagate Technology Holdings Plc (NASDAQ: STX), Chegg, Inc. (NYSE: CHGG), and Relmada...
Jun 17, 2023 07:15 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jun 14, 2023 02:30 pm ET
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD
NEW YORK, June 14, 2023 /PRNewswire/ --
Jun 12, 2023 01:00 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jun 10, 2023 04:59 pm ET
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) resulting from allegations that Relmada may have issued...
Jun 08, 2023 07:30 am ET
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
CORAL GABLES, Fla., June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Goldman Sachs Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Wednesday, June 14, 2023, at 3:20pm PT / 6:20pm ET in Dana Point, CA. Please find additional details about the event below.
Jun 05, 2023 08:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
Jun 04, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), Bowlero Corp. (NYSE: BOWL), and Integra LifeSciences Holdings Corp. (NASDAQ: IART)....
Jun 04, 2023 12:30 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
Jun 03, 2023 12:12 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) resulting from allegations that Relmada may have issued materially...
Jun 03, 2023 06:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
Jun 02, 2023 08:00 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMD
NEW YORK, June 2, 2023 /PRNewswire/ --
Jun 02, 2023 07:30 am ET
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
CORAL GABLES, Fla., June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY. Please find additional details about the event below.
May 31, 2023 05:00 pm ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 30, 2023 06:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
NEW YORK, May 30, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NASDAQ: RLMD).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 28, 2023 09:45 pm ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 28, 2023 03:12 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
Pomerantz LLP is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NASDAQ: RLMD).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
May 26, 2023 11:15 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 26, 2023 12:30 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 24, 2023 10:40 pm ET
INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 24, 2023 07:30 am ET
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
CORAL GABLES, Fla., May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting. The conference is being held Tuesday, May 30 – Friday, June 2, 2023, in Miami, FL.
May 22, 2023 11:50 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 21, 2023 06:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
Pomerantz LLP is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NASDAQ: RLMD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
May 20, 2023 07:05 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), and Sanmina Corporation (NASDAQ: SANM). Our investigations concern whether these...
May 19, 2023 02:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
NEW YORK , May 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NASDAQ: RLMD).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 16, 2023 01:15 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 16, 2023 05:45 am ET
RLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
NEW YORK, May 16, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) violated federal securities laws.
May 15, 2023 05:45 am ET
RLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
NEW YORK, May 15, 2023 /PRNewswire/ -- Attention Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) shareholders:
May 14, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Cutera, Inc. (NASDAQ: CUTR), and Relmada Therapeutics, Inc. (NYSE: RLMD). Our...
May 13, 2023 03:30 pm ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 12, 2023 07:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
Pomerantz LLP is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NASDAQ: RLMD).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
May 12, 2023 06:00 pm ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 12, 2023 05:45 am ET
RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Relmada Therapeutics, Inc. (NYSE: RLMD)
May 11, 2023 04:01 pm ET
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
CORAL GABLES, Fla., May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023. The Company will host a conference call today, Thursday, May 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
May 11, 2023 11:08 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD). Investors who purchased Relmada securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg
May 11, 2023 01:30 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 10, 2023 07:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
NEW YORK, May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NASDAQ: RLMD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
May 10, 2023 05:45 am ET
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Relmada Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NYSE: RLMD)
NEW YORK, May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Relmada Therapeutics, Inc.:
May 10, 2023 02:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
May 09, 2023 09:00 pm ET
RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) on behalf of Relmada stockholders. Our investigation concerns whether Relmada has violated the federal securities laws and/or engaged in other unlawful business practices.
May 09, 2023 05:45 am ET
RLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
NEW YORK, May 9, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) violated federal securities laws.
May 08, 2023 07:30 am ET
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
CORAL GABLES, Fla., May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11th, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023.
May 08, 2023 05:45 am ET
RLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
NEW YORK, May 8, 2023 /PRNewswire/ -- Attention Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NASDAQ: RLMD) shareholders:
May 07, 2023 10:00 pm ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 05, 2023 05:45 am ET
RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, May 5, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Relmada Therapeutics, Inc. (NYSE: RLMD)
May 04, 2023 05:45 am ET
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
NEW YORK, May 4, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws.
May 03, 2023 05:18 pm ET
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Relmada Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NYSE: RLMD)
NEW YORK, May 3, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Relmada Therapeutics, Inc.:
May 03, 2023 03:00 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
May 01, 2023 04:35 pm ET
RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) resulting from allegations that Relmada may have issued materially misleading business information to the investing public.
Apr 28, 2023 07:00 am ET
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
NEW YORK, April 28, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws.
Apr 28, 2023 02:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ: RLMD) for violations of the securities laws.
Apr 27, 2023 09:51 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ:
Apr 26, 2023 06:10 pm ET
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
NEW YORK, April 26, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws.
Apr 26, 2023 05:33 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ:
Apr 26, 2023 05:18 am ET
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) concerning possible violations of federal securities laws. Before market opened on October 13, 2022,...
Mar 23, 2023 04:01 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
CORAL GABLES, Fla., March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022. The Company will host a conference call today, Thursday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Mar 17, 2023 08:30 am ET
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
CORAL GABLES, Fla., March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022 after the market close on Thursday, March 23, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Thursday, March 23, 2023.
Jan 12, 2023 07:00 am ET
Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors.
Jan 09, 2023 07:00 am ET
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program. 
Dec 07, 2022 03:05 pm ET
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET
Nov 10, 2022 03:05 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
CORAL GABLES, Fla., Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and nine months ended September 30, 2022. The Company will host a conference call today, Thursday, November 10, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Nov 08, 2022 03:15 pm ET
Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
CORAL GABLES, Fla., Nov. 8, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2022 after the market close on Thursday, November 10, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, November 10, 2022.
Oct 13, 2022 07:00 am ET
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
RELIANCE I and II Adjunctive MDD Trials Continue to Advance
Sep 20, 2022 08:30 am ET
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
CORAL GABLES, Fla., Sept. 20, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completion of patient treatment in RELIANCE III, a monotherapy registrational Phase 3 trial evaluating REL-1017, the Company's novel NMDA receptor (NMDAR) channel blocker, for major depressive disorder (MDD). Relmada expects to report top-line data from the RELIANCE III trial early next quarter.  
Aug 11, 2022 04:15 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
CORAL GABLES, Fla., Aug. 11, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and six months ended June 30, 2022. The Company will host a conference call today, Thursday, August 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Aug 09, 2022 08:30 am ET
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
CORAL GABLES, Fla., Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to REL-1017, the Company's novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment major depressive disorder (MDD).
Aug 05, 2022 08:30 am ET
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
CORAL GABLES, Fla., Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter and six months ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, August 11, 2022.
Jul 21, 2022 08:30 am ET
Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022
Jun 07, 2022 08:30 am ET
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
CORAL GABLES, Fla., June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 10:40am PT / 1:40pm ET. Please find additional details about the event below.
Jun 02, 2022 08:30 am ET
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
CORAL GABLES, Fla., June 2, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 4:00pm ET. Please find additional details about the event below.
May 25, 2022 08:30 am ET
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
CORAL GABLES, Fla., May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented virtually in two poster presentations at the American Society of Clinical Psychopharmacology 2022 Annual Meeting. The conference is being held Tuesday, May 31, 2022, through Friday, June 3, 2022, in Scottsdale, AZ, and virtually.
May 05, 2022 04:01 pm ET
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
CORAL GABLES, Fla., May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2022. The Company will host a conference call today, Thursday, May 5, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Apr 29, 2022 08:30 am ET
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
CORAL GABLES, Fla., April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today the publication of REL-1017 preclinical data in the peer-reviewed journal, Frontiers in Pharmacology. The article is titled, "REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats," and is available online at: Frontiers | REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats | Ph
Apr 28, 2022 09:00 am ET
Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
CORAL GABLES, Fla., April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, May 5, 2022.
Apr 04, 2022 09:00 am ET
Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
CORAL GABLES, Fla., April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. The conference is being held Monday, April 4, 2022, through Wednesday, April 6, 2022, in Oxford, United Kingdom, and online.
Mar 23, 2022 04:05 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021. The Company will host a conference call today, Wednesday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Mar 16, 2022 08:30 am ET
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Wednesday, March 23, 2022. 
Mar 10, 2022 07:30 am ET
Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively. Please find additional details about the events below.
Feb 23, 2022 05:31 am ET
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
CORAL GABLES, Fla., Feb. 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).
Feb 10, 2022 07:30 am ET
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time.
Dec 22, 2021 08:02 am ET
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
CORAL GABLES, Fla., Dec. 22, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of Phase 2 data from the clinical study of REL-1017 as adjunctive treatment for patients with major depressive disorder (MDD) in the peer-reviewed American Journal of Psychiatry, the most widely read psychiatric journal in the world. The article is titled, "REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2a Double-Blind Randomiz
Dec 15, 2021 09:20 am ET
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $172.5 Million Upsized Public Offering Underwritten by Goldman Sachs and Jefferies
Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, in an upsized underwritten public offering. The...
Dec 14, 2021 07:30 am ET
Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
CORAL GABLES, Fla., Dec. 14, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the closing of a previously announced upsized underwritten public offering of 10,147,059 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,323,529 additional shares of common stock, at a public offering price of $17.00 per share. The gross proceeds to Relmada from the offering, before deducting the underwriting discounts and commissions an
Dec 08, 2021 10:21 pm ET
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other expenses payable by Relmada, are expected to be approximately $150 million. All of the shares in the offering are being sold by Relmada.
Dec 08, 2021 04:19 pm ET
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten...
Dec 01, 2021 07:30 am ET
Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology
CORAL GABLES, Fla., Dec. 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that the data related to the recently completed human abuse potential (HAP) study evaluating REL-1017—the company's lead product candidate—versus oxycodone, will be presented in a poster presentation at the 60th Annual Meeting of the American College of Neuropsychopharmacology, which is taking place December 5-8, 2021, in San Juan, Puerto Rico. The poster session will be held on Tuesday, Decembe
Nov 11, 2021 03:01 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
CORAL GABLES, Fla., Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and nine months ended September 30, 2021.
Nov 09, 2021 08:00 am ET
Relmada Therapeutics to Present at the Jefferies London Healthcare Conference
CORAL GABLES, Fla., Nov. 9, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will present at the Jefferies London Healthcare Conference on November 17th, 2021 at 8:00am Eastern Time.
Nov 04, 2021 08:00 am ET
Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
CORAL GABLES, Fla., Nov. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2021 after the market close on Thursday, November 11, 2021. The company will host a conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, November 11, 2021.
Oct 29, 2021 08:30 am ET
Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress
CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress. The poster session will be held in-person and virtually on Friday, November 5, 2021, from 4:00 to 5:30 PM MST in Colorado Springs, CO. In addition, Relmada is hosting an interactive exhibit booth both in-person and virtually
Oct 04, 2021 08:30 am ET
Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder
CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided regulatory and development updates regarding its ongoing late-stage clinical program for REL-1017 in major depressive disorder (MDD).
Sep 17, 2021 08:00 am ET
Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
CORAL GABLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the annual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, on September 21, 2021, at 12:25 pm ET.
Sep 03, 2021 08:15 am ET
Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the 19th Annual Morgan Stanley Global Healthcare Conference, on September 10, 2021, at 12:30 pm Eastern Time.
Aug 10, 2021 04:05 pm ET
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and six months ended June 30, 2021.
Aug 05, 2021 04:15 pm ET
Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter and six-months ended June 30, 2021 after the market close on Tuesday, August 10, 2021. The company will host a conference call and live audio webcast at 4:30 PM Eastern Time on Tuesday, August 10, 2021.
Jul 27, 2021 07:35 am ET
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).  
Jul 20, 2021 08:15 am ET
Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC
NEW YORK, July 20, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.  Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targ
Jun 15, 2021 08:00 am ET
Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting
NEW YORK, June 15, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations at the College on Problems of Drug Dependence (CPDD) 83rd Annual Meeting, which will be held virtually between June 21 through June 24, 2021.
Feb 23, 2021 07:30 am ET
Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.
Dec 07, 2020 07:40 am ET
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the first patient has been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company's lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD). 
Nov 17, 2020 07:30 am ET
Relmada Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
Oct 27, 2020 08:30 am ET
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the expansion of its leadership team with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and Marco Pappagallo, M.D., as Acting Chief Medical Officer. The Company also provided an update of upcoming milestones for the REL-1017 program.
Jul 13, 2020 08:30 am ET
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."
Jun 23, 2020 08:30 am ET
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antagonist, in a Major Global Market
Jun 23, 2020 08:30 am ET
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antagonist, in a Major Global Market
Jun 09, 2020 08:34 am ET
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
NEW YORK, June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.
May 29, 2020 08:54 am ET
Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present a corporate overview at the Jefferies 2020 Virtual Healthcare Conference, being held June 2-4, 2020.
May 27, 2020 08:00 am ET
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
NEW YORK, May 27, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 (dextromethadone) for the adjunctive treatment of major depressive disorder (MDD) patients.  The Company can proceed into Phase 3 without conducting additional clinical studies, and the FDA and Relmada are aligned on all key aspects of this planned Phase
May 26, 2020 08:00 am ET
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Molly Harper as Executive Vice President of Operations. Ms. Harper will oversee operations across the functions of the Company. 
May 21, 2020 12:15 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, May 21, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD).
Apr 28, 2020 08:30 am ET
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
NEW YORK, April 28, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs.  Dr. Walter will provide oversight for all U.S. and international regulatory strategy and operations.  He has more than 30 years of experience in the biopharmaceutical industry, including 20 years in global regulatory affairs leading small molecule products and biologics, including antibodies and gene
Mar 31, 2020 08:30 am ET
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
NEW YORK, March 31, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as  Senior Vice President, Clinical Development and Safety.  Dr. de Somer will oversee Clinical Development and Safety at Relmada. He has over 30 years of experience in global clinical development strategy, design, execution, and evaluation.
Mar 24, 2020 08:30 am ET
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
NEW YORK, March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron, Ph.D., as Vice President of Drug Development.  Dr. Caron has 30 years of experience in biopharmaceutical development.
Dec 10, 2019 08:00 am ET
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing depression and central nervous system disease therapies, in the successful completion of an underwritten...
Oct 17, 2019 08:30 am ET
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Relmada Therapeutics Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today that the Relmada team will ring the NASDAQ stock market opening bell tomorrow, Friday, October 18, 2019, at 9:30 AM ET, to commemorate the Company's recent uplisting to the NASDAQ Capital Market.
Oct 15, 2019 08:00 am ET
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today reported top-line data from REL-1017-202, a double-blind, placebo-controlled Phase 2 clinical study evaluating the safety, tolerability and efficacy of two doses of REL-1017 (dextromethadone), 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with treatment resistant depression.
Oct 14, 2019 04:49 pm ET
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will release top-line data from its Phase 2 study of REL-1017 in patients with treatment resistant depression tomorrow, October 15, 2019, before the market opens. 
Oct 10, 2019 08:30 am ET
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
NEW YORK, Oct. 10, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announces that the Company's common stock will begin trading on The Nasdaq Capital Market beginning at 9:30 a.m. ET today, Thursday October 10, under its existing symbol, "RLMD." 
Oct 08, 2019 08:28 am ET
Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company's common stock has been approved for listing on The Nasdaq Capital Market. Trading on Nasdaq is expected to begin on Thursday, October 10, under the existing symbol, "RLMD." 
Sep 27, 2019 12:10 pm ET
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that its Board of Directors has approved a 1-for-4 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace on September 30, 2019, whereupon t
Jul 29, 2019 08:00 am ET
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
NEW YORK, July 29, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the last subject has completed dosing with REL-1017 (dextromethadone) in the company's  double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as an adjunctive treatment in patients affected by treatment-resistant depression. The company expects to announce topline results from the study in Q3 2019.
Apr 16, 2019 08:00 am ET
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
NEW YORK, April 16, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that results of its N-methyl-D-aspartate receptor (NMDAR) antagonist REL1017 (dextromethadone) single ascending dose and multiple ascending dose studies were accepted for publication in the peer reviewed  Journal of Clinical Psychopharmacology.  REL1017 is Relmada's lead product candidate currently in a Phase 2 study in individuals with major depressive disorder (MDD) who have not res
Apr 03, 2019 08:00 am ET
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
NEW YORK, April 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Gina DiGuglielmo has joined the company as vice president and head of clinical operations. Ms. DiGuglielmo previously served as clinical operations advisor of Relmada since June 2017.  In her new role, Ms. DiGuglielmo will lead and oversee the clinical operations for Relmada's lead product candidate dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonis
Jan 02, 2019 07:00 am ET
Relmada Therapeutics to Present at Biotech Showcase 2019
NEW YORK, Jan. 2, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at Biotech Showcase 2019 to be held January 7-9, 2019, at the Hilton San Francisco Union Square.
Dec 12, 2018 07:00 am ET
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that clinical data demonstrating increased plasma levels of brain derived neurotrophic factor (BDNF) in healthy subjects treated with REL-1017 (dextromethadone) were presented at the annual American College of Neuropsychopharmacology meeting. BDNF has been shown to play an important role in the pathophysiology of depression and has been investigated as a biomarker for depression. 
Oct 02, 2018 08:00 am ET
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
NEW YORK, Oct. 2, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will present clinical data demonstrating increased plasma levels of brain derived neurotrophic factor (BDNF) in healthy subjects treated with d-methadone (REL-1017). BDNF has been shown to play an important role in the pathophysiology of depression. Since its plasma levels appear to decrease in individuals with depression and increase with treatment response, BDNF has been inves
Sep 18, 2018 08:00 am ET
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received treatment in its Phase 2 study of dextromethadone (REL-1017) in depression.  None of the treated subjects experienced either serious adverse events or psychotomimetic adverse events. Overall REL-1017 continues to show an acceptable safety and tolerability profile, which confirms what was previou
Aug 09, 2018 08:00 am ET
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK, Aug. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the State Intellectual Property Office of China has issued a Decision to Grant for Relmada's patent application number 201380061197.3, titled "d-Methadone for the Treatment of Psychiatric Symptoms". The patent that will issue from this allowed application provides broad coverage in China for d-methadone (dextromethadone, REL-1017), a novel once-a-day oral direct inhibitor of activa
Jun 27, 2018 08:00 am ET
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
NEW YORK, June 27, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the dosing of the first patient in the Company's Phase 2 clinical study to evaluate the safety and efficacy of REL-1017 (dextromethadone) as an adjunctive treatment in patients affected by Major Depressive Disorder (MDD) that did not respond to currently marketed antidepressants.
Apr 03, 2018 08:00 am ET
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
NEW YORK, April 3, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Ottavio Vitolo has joined the company as senior vice president, head of research and development and chief medical officer. Dr. Vitolo previously served as executive clinical advisor of Relmada since June 2017. In this new role, Dr. Vitolo will manage the clinical development program for Relmada's lead product candidate, dextromethadone (REL-1017), a novel, N-methyl-D-aspartat
Jan 17, 2018 07:00 am ET
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
NEW YORK, Jan. 17, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has acquired the global rights to develop and market dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of neurological conditions including certain rare diseases with symptoms affecting the CNS.
Jan 09, 2018 07:00 am ET
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the European Patent Office has issued a notice of allowance for patent application number 13773543.7 for "D-methadone for the treatment of psychiatric symptoms." The patent provides broad coverage in Europe for d-Methadone (dextromethadone, REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a range of psychological and
Oct 27, 2017 09:00 am ET
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK, Oct. 27, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that IP Australia has issued a notice of acceptance for patent application number 2013323645 for "D-methadone for the treatment of psychiatric symptoms." The patent application provides broad coverage for d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, in Australia as a treatment for symptoms associated with a range of psychological and psyc
Oct 05, 2017 09:00 am ET
Relmada Therapeutics Announces $6.9 Million Private Placement
NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced a private placement of convertible promissory notes and warrants to new and existing accredited investors, which will result in total gross proceeds of approximately $6.9 million.
Jun 28, 2017 09:00 am ET
Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program
NEW YORK, June 28, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Maurizio Fava has been named chair of the newly formed Dextromethadone Scientific Advisory Board of the company.  In this role, Dr. Fava will be a key advisor for the development program for dextromethadone (REL 1017), including preclinical and clinical research, and regulatory strategies, in coordination with Relmada's established team of advisors an
Jun 21, 2017 09:00 am ET
Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics
NEW YORK, June 21, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Ottavio Vitolo has been appointed executive clinical advisor to the company.  In this role, Dr. Vitolo will guide the clinical development program and preclinical research, including trial design and execution for dextromethadone (REL 1017), a novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed as rapidly acting oral agent for the treatment of depression and
Jun 15, 2017 09:30 am ET
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
NEW YORK, June 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.
May 18, 2017 09:00 am ET
Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company
NEW YORK, May 18, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, and Laidlaw & Company (UK) Ltd. ("Laidlaw"), today announced final disposition of all claims and counterclaims in all legal proceedings related to Relmada Therapeutics, Inc. v. Laidlaw & Company (UK) Ltd., et al., Case No.1:16-CV-07767, pending in the United States District Court for the Southern District of New York.  
Apr 13, 2017 09:00 am ET
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder
NEW YORK, April 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the company's novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder.
Feb 15, 2017 08:00 am ET
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference
NEW YORK, Feb. 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, CEO of Relmada Therapeutics, will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 1:45pm Eastern Time in Track 1 - Tribeca at the Convene Conference Center in New York City.
Feb 13, 2017 08:30 am ET
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the company will participate in the BIO CEO and Investor Conference to be held February 13-14, 2017 at the Waldorf Astoria in New York City.
Jan 25, 2017 05:41 pm ET
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone
NEW YORK, Jan. 25, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Investigational New Drug (IND) application for d-Methadone (REL-1017 dextromethadone), the company's novel, N-methyl-D-aspartate (NMDA) receptor antagonist, has been cleared by the U.S. Food and Drug Administration (FDA). The company is now authorized to advance the development program for d-Methadone to a Phase 2a proof of concept clinical study in patients with treatment res
Jan 24, 2017 04:30 pm ET
Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
NEW YORK, Jan. 24, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, is pleased to announce that after an exchange of correspondence and a recent meeting with the U.S. Food and Drug Administration (FDA), a path has been defined for the clinical development of LevoCap ER (REL-1015, levorphanol extended release, abuse deterrent capsules) and the objective of a new drug application (NDA) filing is achievable.  
Jan 05, 2017 08:30 am ET
Relmada Therapeutics to Present at Biotech Showcase 2017
NEW YORK, Jan. 5, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.
Nov 29, 2016 08:30 am ET
Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference
NEW YORK, Nov. 29, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at the LD Micro Main Event Conference to be held December 6-8, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Oct 27, 2016 09:30 am ET
Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention
NEW YORK, Oct. 27, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at the Sidoti & Company Fall 2016 Emerging Growth Convention to be held Tuesday, November 1, 2016, at the Mariott Marquis in New York City.
Oct 19, 2016 09:30 am ET
Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms
NEW YORK, Oct. 19, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,468,611 for "d-Methadone for the Treatment of Psychiatric Symptoms." The patent contains claims that provide broad coverage for d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, as a treatment for psychological and psychiatric disorders, comprising depression, anxiety, fatigue,
Oct 06, 2016 09:30 am ET
Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum
NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at the 15th Annual BIO Investor Forum to be held October 18-19, 2016, at the Westin St. Francis, San Francisco.
Sep 28, 2016 09:30 am ET
Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston
NEW YORK, Sept. 28, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Richard Mangano, the company's chief scientific officer, will participate in a panel of thought leaders regarding N-methyl-D-aspartate (NMDA) receptor antagonists as a new therapeutic option to treat depression. The panel discussion will be held at the Neuro Advance Boston Conference on October 5, 2016, held at Harvard Medical School.
Sep 22, 2016 09:00 am ET
Relmada Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
NEW YORK, Sept. 22, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company will present at the 2016 Ladenburg Thalmann Healthcare Conference being held September 27, 2016 at the Sofitel Hotel in New York City.
Sep 20, 2016 09:30 am ET
Relmada Therapeutics to Present at the 2016 Aegis Growth Conference
NEW YORK, Sept. 20, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company will present at the 2016 Aegis Growth Conference being held September 20-22, 2016 at The Encore at Wynn Las Vegas, Las Vegas, Nevada.
Sep 14, 2016 09:30 am ET
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
NEW YORK, Sept. 14, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it has filed a motion to amend its amended complaint against Laidlaw & Company (UK) Ltd. ("Laidlaw") in the U.S. District Court for the District of Nevada.  The motion to file a second amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court. The proposed second amended complaint, dated September 6, 2016 (the "Proposed Second
Sep 12, 2016 09:30 am ET
Pharmaceutical Industry Leader Ronald M. Burch Joins Relmada Therapeutics Advisory Team
NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today announced that Ronald M. Burch M.D., Ph.D., formerly Chief Medical Officer at Naurex, Inc. recently acquired by Allergan, has joined Relmada as an advisory partner.
Sep 07, 2016 09:30 am ET
Relmada Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on being held September 11-13, 2016 at the Lotte New York Palace Hotel.
Jul 06, 2016 09:30 am ET
Relmada Therapeutics Secures First European Patent Covering LevoCap ER
NEW YORK, July 6, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan). The Patent (EP 2 448 406 B1), titled "Extended Release Oral Pharmaceutical Compositions of 3-hydroxy-N-methylmorphinan" broadly covers Relmada's SECUREL™ technology platform and LevoCap ER (REL-1015, levorpha
Jun 27, 2016 09:30 am ET
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression
NEW YORK, June 27, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that its patent application relating to d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).
Jun 07, 2016 09:30 am ET
Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
NEW YORK, June 7, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes z
Jun 01, 2016 09:30 am ET
Relmada Therapeutics to Present at the LD Micro Invitational Conference
NEW YORK, June 1, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the LD Micro Invitational Conference on Tuesday, June 7, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
May 26, 2016 09:30 am ET
Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
NEW YORK, May 26, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.
May 16, 2016 09:30 am ET
Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
NEW YORK, May 16, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.
May 04, 2016 09:30 am ET
Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
NEW YORK, May 4, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the results of an in vivo study showing that administration of d-Methadone (REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist, results in antidepressant-like effects.  Results are shown to be comparable to those achieved in similar treatment models using ketamine.
Apr 28, 2016 09:30 am ET
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
NEW YORK, April 28, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will present at the Joseph Gunnar "Pioneers 2016" Conference on May 5, 2016 at the New York Palace Hotel in New York City.
Apr 26, 2016 09:30 am ET
Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
NEW YORK, April 26, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.
Apr 21, 2016 09:00 am ET
Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the...
Apr 20, 2016 09:30 am ET
Relmada Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
NEW YORK, April 20, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day during the first week of May 2016 in New York City. Members of Relmads's senior management, research teams, and scientific advisors will provide a corporate update and in-depth reviews of the Company's R&D programs.
Apr 14, 2016 09:30 am ET
Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
NEW YORK, April 14, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, today provided investors with an update regarding the Company's qualification for up-listing to The Nasdaq Capital Market ("Nasdaq"). As previously disclosed, the Company submitted an initial listing application with Nasdaq in the second half of 2015. The Company now believes that it satisfies each of the exchange's applicable listing requirements, with the exception of the $4.00 bid price requirement. In accordance with the
Mar 08, 2016 08:00 am ET
Relmada Therapeutics to Present at the 28th Annual ROTH Conference
NEW YORK, March 8, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that the Company's management will present at the 28th Annual ROTH Conference, which is being held March 13-16, 2016 in Orange County, CA.
Mar 01, 2016 08:00 am ET
Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated
NEW YORK, March 1, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company), a clinical-stage company developing novel therapies for the treatment of neuropathic and chronic pain, announced today the publication of the full results from a safety and tolerability Phase I trial of d-methadone (dextromethadone, REL-1017) in patients suffering from chronic pain. Results published in the Journal of Opioid Management[1] demonstrated that d-methadone appears to be safe and well tolerated. The design of the Company's Phase II proof-of-concept study in neuropathic pai
Feb 02, 2016 08:00 am ET
Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
NEW YORK, Feb. 2, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 3:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More